Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24619078 | 1.00 | TSHR (0.45) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL29333971 | 0.94 | ALDH1A1 (0.42) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL1104713 | 0.88 | TP53 (0.39) | TSHRALDH1A1MAPK1GAAFABP6 | |
| SCHEMBL12384404 | 0.88 | TP53 (0.39) | TSHRALDH1A1MAPK1GAAFABP6 | |
| SCHEMBL2625515 | 0.88 | TP53 (0.39) | TSHRALDH1A1MAPK1GAAFABP6 | |
| SCHEMBL18745363 | 0.85 | TSHR (0.43) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL13225930 | 0.85 | FABP6 (0.43) | TSHRALDH1A1MAPK1GAAFABP6 | |
| SCHEMBL21936034 | 0.82 | GAA (0.42) | TSHRALDH1A1MAPK1GAACYP2C19 | |
| SCHEMBL15177622 | 0.79 | PAX8 (0.32) | TSHRALDH1A1 | |
| SCHEMBL1104697 | 0.75 | TP53 (0.46) | TSHRALDH1A1CYP2C19POLBFABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-9938294-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | TSHR 4538/4885ALDH1A1 2458/4885MAPK1 1392/4885 |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1769/4885ALDH1A1 4703/4885MAPK1 2796/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | TSHR 4766/4885ALDH1A1 2855/4885MAPK1 4363/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | TSHR 4766/4885ALDH1A1 2855/4885MAPK1 4363/4885 |
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | TSHR 4578/4885ALDH1A1 656/4885MAPK1 3584/4885 |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1771/4885ALDH1A1 4459/4885MAPK1 2058/4885 |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | TSHR 1771/4885ALDH1A1 4459/4885MAPK1 2058/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | TSHR 1624/4885ALDH1A1 2349/4885MAPK1 115/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | TSHR 1082/4885ALDH1A1 1168/4885MAPK1 2009/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | TSHR 1771/4885ALDH1A1 4459/4885MAPK1 2058/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | TSHR 4578/4885ALDH1A1 656/4885MAPK1 3584/4885 |
| US-10464947-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | TSHR 1771/4885ALDH1A1 4459/4885MAPK1 2058/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | TSHR 4438/4885ALDH1A1 3165/4885MAPK1 4422/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | TSHR 4766/4885ALDH1A1 2855/4885MAPK1 4363/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | TSHR 1771/4885ALDH1A1 4459/4885MAPK1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.